{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:30:16Z","timestamp":1777627816608,"version":"3.51.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009888","name":"Regione Toscana","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero Dell'Istruzione e del Merito","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>By virtue of their ability to bind different growth factors, morphogens and extracellular matrix proteins, heparan sulfate proteoglycans (HSPGs) play a determinant role in cancer cell differentiation and migration. Despite a strong conceptual basis and promising preclinical results, clinical trials have failed to demonstrate any significant advantage of administering heparin to oncology patients. We exploited our anti-heparan sulfate branched peptide NT4 to test the opposite approach, namely, targeting HSPGs to interfere with their functions, instead of using heparin as a soluble competitor in human cell lines from pancreas adenocarcinoma, colon adenocarcinoma, rhabdomyosarcoma and two different breast cancers. We found that the anti-heparan sulfate peptide NT4 is more effective than heparin for inhibiting cancer cell adhesion, directional migration, colony formation and even cell growth, suggesting that targeting cell membrane HSPGs may be a more effective anti-metastatic strategy than using soluble heparin. Analysis of NT4 effects on cancer cell directional migration, associated to cellular distribution of HSPGs and cadherins in different migrating cancer cell lines, provided further indications on the molecular basis of HSPG functions, which may explain the efficiency of the HSPG targeting peptide.<\/jats:p>","DOI":"10.3389\/fcell.2024.1505680","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:23:44Z","timestamp":1736317424000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting heparan sulfate proteoglycans as an effective strategy for inhibiting cancer cell migration and invasiveness compared to heparin"],"prefix":"10.3389","volume":"12","author":[{"given":"Lorenzo","family":"Depau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jlenia","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Falciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Mandarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Zanchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Francesca","family":"Paolocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Garf\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Bracci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1083\/jcb.200610076","article-title":"Syndecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix","volume":"177","author":"Bass","year":"2007","journal-title":"J. Cell Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41467-020-20362-2","article-title":"Filopodia-based contact stimulation of cell migration drives tissue morphogenesis","volume":"12","author":"Bischoff","year":"2021","journal-title":"Nat. Commun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0194744","DOI":"10.1371\/journal.pone.0194744","article-title":"The GAG-specific branched peptide NT4 reduces angiogenesis and invasiveness of tumor cells branched peptide NT4 reduces angiogenesis and invasiveness of tumor cells","volume":"13","author":"Bracci","year":"2018","journal-title":"PLoS ONE"},{"key":"B4","doi-asserted-by":"publisher","first-page":"27174","DOI":"10.1038\/srep27174","article-title":"Insights into the role of sulfated glycans in cancer cell adhesion and migration through use of branched peptide probe","volume":"6","author":"Brunetti","year":"2016","journal-title":"Sci. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"173507","DOI":"10.1155\/2015\/173507","article-title":"Neurotensin branched peptide as a tumor-targeting agent for human bladder cancer","volume":"2015","author":"Brunetti","year":"","journal-title":"Biomed. Res. Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"17736","DOI":"10.1038\/srep17736","article-title":"Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug","volume":"5","author":"Brunetti","year":"","journal-title":"Sci. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3389\/fonc.2019.00843","article-title":"Unraveling heparan sulfate proteoglycan binding motif for cancer cell selectivity","volume":"9","author":"Brunetti","year":"2019","journal-title":"Front. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12951-018-0346-1","article-title":"Near-infrared quantum dots labelled with a tumor selective tetrabranched peptide for in vivo imaging","volume":"16","author":"Brunetti","year":"2018","journal-title":"J. Nanobiotechnology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.3390\/ijms21186588","article-title":"Heparan sulfate proteoglycan signaling in tumor microenvironment","volume":"21","author":"De Pasquale","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"15997","DOI":"10.1021\/acs.jmedchem.0c01848","article-title":"Heparan sulfate proteoglycans can promote opposite effects on adhesion and directional migration of different cancer cells","volume":"63","author":"Depau","year":"2020","journal-title":"J. Med. Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"76141","DOI":"10.18632\/oncotarget.19056","article-title":"Coupling to a cancer-selective heparan-sulfate-targeted branched peptide can by-pass breast cancer cell resistance to methotrexate","volume":"8","author":"Depau","year":"2017","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mdx716","article-title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","volume":"29","author":"Ek","year":"2018","journal-title":"Ann. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/cmdc.201000463","article-title":"Target-selective drug delivery through liposomes labeled with oligobranched neurotensin peptides","volume":"6","author":"Falciani","year":"2011","journal-title":"ChemMedChem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1021\/jm400329p","article-title":"Cancer selectivity of tetrabranched neurotensin peptides is generated by simultaneous binding to sulfated glycosaminoglycans and protein receptors","volume":"56","author":"Falciani","year":"2013","journal-title":"J. Med. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cmdc.200900527","article-title":"Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumor-selective agents","volume":"5","author":"Falciani","year":"","journal-title":"ChemMedChem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1158\/1535-7163.MCT-07-0164","article-title":"Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting","volume":"6","author":"Falciani","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2174\/156800910793605875","article-title":"Modular branched neurotensin peptides for tumor target tracing and receptor-mediated therapy: a proof-of-concept","volume":"10","author":"Falciani","year":"","journal-title":"Curr. Cancer Drug Targets."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1038\/s41467-020-19114-z","article-title":"E-cadherin focuses protrusion formation at the front of migrating cells by impeding actin flow","volume":"11","author":"Grimaldi","year":"2020","journal-title":"Nat. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"109822","DOI":"10.1016\/j.cellsig.2020.109822","article-title":"Cell-surface heparan sulfate proteoglycans as multifunctional integrators of signaling in cancer","volume":"77","author":"Hassan","year":"2021","journal-title":"Cell Signal"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3390\/ijms18071361","article-title":"Epigenetic regulation of the biosynthesis and enzymatic modification of heparan sulfate proteoglycans: implications for tumorigenesis and cancer biomarkers","volume":"18","author":"Hull","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.3390\/cancers13133322","article-title":"Syndecan-4 in tumor cell motility","volume":"13","author":"Keller-Pinter","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.3390\/cancers13071711","article-title":"RGD-binding integrins revisited: how recently discovered functions and novel synthetic ligands (Re-)Shape an ever-evolving field","volume":"13","author":"Ludwig","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/19336918.2020.1767489","article-title":"The anti-cancer properties of heparin and its derivatives: a review and prospect","volume":"14","author":"Ma","year":"2020","journal-title":"Cell Adh Migr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"778752","DOI":"10.3389\/fonc.2021.778752","article-title":"Heparan sulfate biosynthesis and sulfation profiles as modulators of cancer signalling and progression","volume":"11","author":"Marques","year":"2021","journal-title":"Front. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1801220","DOI":"10.1183\/13993003.01220-2018","article-title":"Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial","volume":"52","author":"Meyer","year":"2018","journal-title":"Eur. Respir. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/ph10040078","article-title":"Heparin mimetics: their therapeutic potential","volume":"10","author":"Mohamed","year":"2017","journal-title":"Pharm. (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1055\/s-0040-1709712","article-title":"The efficacy and safety of low molecular weight heparin administration to improve survival of cancer patients: a systematic review and meta-analysis","volume":"120","author":"Montroy","year":"2020","journal-title":"Thromb. Haemost."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/15384047.2020.1838034","article-title":"Heparan sulfate proteoglycans as targets for cancer therapy: a review","volume":"21","author":"Onyeisi","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2020.03.005","article-title":"Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma","volume":"132","author":"O'Reilly","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e703","DOI":"10.1016\/S2352-3026(20)30276-3","article-title":"Heparins as cancer therapy: in theory, they should have worked","volume":"7","author":"Posch","year":"2020","journal-title":"Lancet Haematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1242\/dev.098178","article-title":"Heparan sulfate proteoglycans: a sugar code for vertebrate development?","volume":"142","author":"Poulain","year":"2015","journal-title":"Development"},{"key":"B32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.thromres.2020.07.008","article-title":"A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models","volume":"195","author":"Ripsman","year":"2020","journal-title":"Thromb. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e746","DOI":"10.1016\/S2352-3026(20)30293-3","article-title":"Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis","volume":"7","author":"Sch\u00fcnemann","year":"2020","journal-title":"Lancet Haematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-bioeng-071516-044610","article-title":"Sulfation of glycosaminoglycans and its implications in human Health and disorders","volume":"19","author":"Soares da Costa","year":"2017","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"B35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1369\/0022155420946403","article-title":"Glycosaminoglycan-protein interactions: the first draft of the glycosaminoglycan interactome","volume":"69","author":"Vallet","year":"2021","journal-title":"J. Histochem Cytochem"},{"key":"B36","doi-asserted-by":"publisher","first-page":"C1187","DOI":"10.1152\/ajpcell.00063.2022","article-title":"Glycosaminoglycans in cancer therapy","volume":"322","author":"Wieboldt","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1505680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:23:48Z","timestamp":1736317428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1505680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":36,"alternative-id":["10.3389\/fcell.2024.1505680"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2024.1505680","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"article-number":"1505680"}}